Immunosuppression and the additive effect of plasma exchange in treatment of rapidly progressive glomerulonephritis. 1982

H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell

Attempts were made to evaluate the separate effect on kidney function of immunosuppressive treatment (IS) and plasma exchange (PE) in 27 patients with rapidly progressive glomerulonephritis (RPGN). Twenty-four of the patients were treated with PE. Initial IS was supplemented with PE within 6-12 days in 5 patients, and after at least 14 days in 13. Because of suspected septicemia, 2 patients were first treated with PE, and IS was not initiated until the possibility of septicemia had been excluded. In 4 severely ill patients wih rapid clinical deterioration, both treatments were started simultaneously. Twenty patients improved during one or both treatments, 4 with IS alone, 2 with IS and doubtfully with PE, 3 with IS and probably also with PE, 5 both with IS and PE and one with PE alone. In 5 patients the individual effects of IS and PE could not be evaluated. In another 2 patients the combined treatment seemed to influence the course favourably. In the remaining 7 patients the effect of the treatment was doubtful or nil. Two further patients with Goodpasture's syndrome were treated. They were admitted late, and both kinds of treatment were instituted simultaneously. One of them died in respiratory insufficiency, the other remained oliguric while the pulmonary changes faded. Thus, PE added a positive effect to IS in several patients with RPGN. The treatment had few and mostly mild side-effects.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D005260 Female Females

Related Publications

H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
January 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
January 2013, Contributions to nephrology,
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
January 1990, Progress in clinical and biological research,
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
January 1988, Clinical nephrology,
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
August 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis,
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
November 1984, British medical journal (Clinical research ed.),
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
January 1985, Life support systems : the journal of the European Society for Artificial Organs,
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
November 1981, Deutsche medizinische Wochenschrift (1946),
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
July 1983, The International journal of artificial organs,
H Thysell, and P Bygren, and U Bengtsson, and T Lindholm, and M Norlin, and M Jonsson, and C Brun, and S Larsen, and F Jørgensen, and A Sjöholm, and A B Laurell
June 1982, Die Medizinische Welt,
Copied contents to your clipboard!